Detection of BMAA in the human central nervous system  by Berntzon, L. et al.
Neuroscience 292 (2015) 137–147DETECTION OF BMAA IN THE HUMAN CENTRAL NERVOUS SYSTEML. BERNTZON, a* L. O. RONNEVI, b B. BERGMAN a AND
J. ERIKSSON a
aDepartment of Ecology, Environment and Plant
Sciences, Stockholm University, SE-10691 Stockholm, Sweden
bDepartment of Clinical Neuroscience, Karolinska Institute,
SE-17176 Stockholm, SwedenAbstract—Amyotrophic lateral sclerosis (ALS) is an extre-
mely devastating neurodegenerative disease with an
obscure etiology. The amino acid b-N-methyl-L-alanine
(BMAA) produced by globally widespread phytoplankton
has been implicated in the etiology of human motor neuron
diseases. BMAA was recently proven to be present in Baltic
Sea food webs, ranging from plankton to larger Baltic Sea
organisms, some serving as important food items (ﬁsh) for
humans. To test whether exposure to BMAA in a Baltic Sea
setting is reﬂected in humans, blood and cerebrospinal ﬂuid
(CSF) from individuals suﬀering from ALS were analyzed,
together with sex- and age-matched individuals not inﬂicted
with ALS. Ultra high performance liquid chromatography-
tandem mass spectrometry (UHPLC-MS/MS) and multiple
reaction monitoring (MRM), in conjunction with diagnostic
transitions revealed BMAA in three (12%) of the totally 25
Swedish individuals tested, with no preference for those suf-
fering from ALS. The three BMAA-positive samples were all
retrieved from the CSF, while BMAA was not detected in the
blood. The data show that BMAA, potentially originating from
Baltic Sea phytoplankton, may reach the human central ner-
vous system, but does not lend support to the notion that
BMAA is resident speciﬁcally in ALS-patients. However,
while dietary exposure to BMAA may be intermittent and, if
so, diﬃcult to detect, our data provide the ﬁrst demonstration
of BMAA in the central nervous system of human individuals
ante mortem quantiﬁed with UHPLC–MS/MS, and therefore
calls for extended research eﬀorts.  2015 The
Authors. Published by Elsevier Ltd. on behalf of IBRO. This
is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/4.0/).
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137INTRODUCTION
The environmental non-protein amino acid b-N-methyl-L-
alanine (BMAA) was initially reported in tropical cycad
plants (Vega and Bell, 1967, see also Marler et al.,
2010; Snyder and Marler, 2011). BMAA has gained
increased attention in recent years as it was found to be
produced by prokaryotic cyanobacteria, including cyano-
bacteria living in symbiosis with cycads (Cox et al.,
2003, 2005; Bergman et al., 2008), as well as globally
widespread free-living cyanobacteria (Cox et al., 2005;
Esterhuizen and Downing, 2008; Metcalf et al., 2008;
Faassen et al., 2009; Jiao et al., 2014). The known pro-
ducers of BMAA have recently expanded to include also
photoautotrophic eukaryotes such as diatoms (Jiang
et al., 2014a) and dinoﬂagellates (Lage et al., 2014).
BMAA producers thus include numerous phytoplanktonic
organisms that constitute fundamental primary producers
at the base of elaborate aquatic food webs.
Despite the widespread occurrence of these
photosynthetic microorganisms in nature, the cellular
and ecological role of BMAA in these organisms
remains enigmatic. The neurotoxic eﬀects and
mechanisms of action of BMAA have been extensively
studied in eukaryotes (in vitro and in vivo) using both
animal test systems (reviewed in Karamyan and Speth,
2008; Chiu et al., 2011) and various human cell lines
(Chiu et al., 2012; Lee and McGeer, 2012; Dunlop et al.,
2013; Mun˜oz-Saez et al., 2013; Okle et al., 2013).
There is considerable evidence for BMAA being a crucial
factor in the pathophysiology of the neurodegenerative
disease amyotrophic lateral sclerosis Parkinsonism
dementia complex (ALS-PDC). This disease was ﬁrst
observed among the native Chamorro population of
Guam (in Western Paciﬁc Ocean) and claimed to be
caused by ingestion of BMAA containing food such as
cycad ﬂour and ﬂying foxes, the latter feeding on cycad
seeds (see e.g., Spencer et al., 1987; Banack et al.,
2006). ALS-PDC has many clinical and neuropathological
features in common with the neurodegenerative diseases
amyotrophic lateral sclerosis (ALS), Parkinson’s and
Alzheimer’s (AD), which are common in all parts of the
world. Consequently, BMAA is now thought to play a pos-
sible role also in the otherwise unclear etiology of these
diseases. Perhaps the most notable observation that sug-
gests a link between BMAA and human neurodegenera-
tion is the claimed consistent presence of BMAA in the
central nervous system (CNS) of patients deceased from
ALS-PDC (Guam), and from those with AD and ALS (USA
and Canada), while BMAA is not detected in controls or in
patients suﬀering from Huntington’s disease, a disorderons.org/licenses/by-nc-sa/4.0/).
138 L. Berntzon et al. / Neuroscience 292 (2015) 137–147with a known direct genetic cause (Cox et al., 2003;
Murch et al., 2004a,b; Pablo et al., 2009). However, as
other studies analyzing similar human CNS based sample
sets have failed to detect BMAA in either patients or
matched controls (Montine et al., 2005; Kushnir and
Bergquist, 2009; Snyder et al., 2009a,b, 2010; Combes
et al., 2014), the occurrence of BMAA in the human
CNS is still under debate as well as the observed
presence of BMAA in patients with neurodegenerative
disorders.
The ﬁrst evidence of the presence of BMAA at
diﬀerent levels in aquatic food webs was found in the
brackish Baltic Sea (Jonasson et al., 2010). Hence,
surrounding inhabitants (today 180 million people in
nine countries) may be exposed to BMAA-amended sta-
ple food items derived from this body of water, such as
shellﬁsh and ﬁsh. The increase in the already massive
summer blooms of cyanobacteria (Kahru and Elmgren,
2014) through eutrophication suggests enhanced BMAA
production and human exposure. Similar BMAA transfer
routes have been conﬁrmed by studies in other geo-
graphic regions and include both marine and limnic
ecosystems (USA and China) (Brand et al., 2010;
Christensen et al., 2012; Mondo et al., 2012; Jiao et al.,
2014; Al-Sammak et al., 2014). Hence, BMAA in the
environment may represent a public health concern
should the connection between environmental BMAA
and neurodegeneration be proven.
To test whether exposure to BMAA in a Baltic Sea
setting is reﬂected in humans, blood and cerebrospinal
ﬂuid (CSF) from individuals suﬀering from ALS, together
with sex- and age-matched individuals not inﬂicted with
ALS (referred to as non-ALS individuals), were analyzed
for BMAA using ultra high performance liquid
chromatography-mass spectrometry (UHPLC-MS/MS).EXPERIMENTAL PROCEDURES
Chemicals
BMAA (L-BMAA hydrochloride B-107) was purchased
from Sigma–Aldrich (Steinheim, Germany), L-2-4-
diaminobutyric acid hydrochloride (DAB) was from Fluka
(#32830; Buchs, Switzerland) and N-(2-aminoethyl)
glycine (AEG) from Tokyo Chemical Industry (A1153;
Tokyo, Japan). Deuterated (D3) BMAA was synthesized
and kindly provided by Dr. K. Bogar (Department of
Organic Chemistry, Stockholm University) and stored as
stock solution at 20 C (760 ng/ml). All reagents used
were of high/highest analytical grade.Material and sample treatment
Cerebrospinal ﬂuid (CSF) was obtained from 12
(Swedish) ALS-patients as well as 13 age- and gender-
matched non-ALS individuals (controls). Whole blood
and plasma were collected from 10 of the ALS-patients
and seven of the controls. CSF and blood were sampled
within the same day from the individual patients and
controls. ALS-patients were diagnosed according to the
revised El Escorial criteria (Brooks et al., 2000) at the
Department of Neurology, (Karolinska UniversityHospital, Sweden). Ethical permission for the study was
obtained from the Stockholm County regional ethics com-
mittee. Samples, including CSF, whole blood and plasma,
were blinded and the identity was not revealed until the
material was fully analyzed and BMAA-negative and
-positive samples identiﬁed. Samples were stored at
20 C and the majority was analyzed within 2 years after
collection (a few within 5–7 years). The extraction proce-
dure for CSF, whole blood and plasma was adapted from
Jiang et al. (2014a) and adjusted to the requirements of
each diﬀerent material in the study as given below.CSF. A volume of 3-ml CSF was sonicated for 2 min at
70% eﬃciency using a Sonopuls, Model HD 2070
(Bandelin Electronic, Berlin, Germany) and the material
was kept cool in an ice/methanol bath to prevent protein
degradation. The cell solution was centrifuged at 4100g
for 30 min at 4 C. The supernatant was transferred into
a new tube with twice the supernatant volume of cold
acetone added. The sample was precipitated at 20 C
overnight and centrifuged at 4100g for 30 min at 4 C.
Even though acetone is a generally eﬃcient agent for
protein precipitation (Sedgwick et al., 1991), small soluble
peptides and protein fragments may escape precipitation.
Therefore, the free fraction was hydrolyzed just as the pro-
tein fraction. For hydrolyzation 600-ll 6 M HCl was added
to both the protein pellet and the (dried) supernatant, and
the samples were hydrolyzed overnight (22 h) at 110 C.
The hydrolyzed samples were lyophilized (CoolSafe,
SCANVAC, Lynge, Denmark) before resuspension in
100-ll borate buﬀer (Waters AccQ-Tag Ultra kit, Waters,
Milford, MA, USA) and 20-ll derivatization agent 6-amino-
quinolyl-N-hydroxysuccinimidyl carbamate (AQC) (Waters
AccQ-Tag Ultra kit, Waters, Milford, MA, USA) was added.
Due to scarce material, only one replicate of each individ-
ual was analyzed.Whole blood and plasma. Aliquots of 100-ll whole
blood/plasma mixed with 400-ll dH2O (HPLC-grade)
were prepared in triplicate. The total dry weight of 100 ll
was approximately 23.3 mg± 0.6 for whole blood and
9.3 mg± 0.1 for plasma, and corresponded to an
average protein pellet dry weight of approximately
18.2 mg ± 1.6 for whole blood and 7.3 mg ± 0.5 for
plasma. Lysis of the red blood cells was achieved by
freeze–thawing in liquid nitrogen (1), however, no lysis
procedure was performed for plasma. Cell debris was
removed by centrifugating (2570g) for 30 min at 4 C.
The supernatant was transferred to a new microtube with
1000 ll (1:2) acetone added to precipitate proteins at
20 C overnight. Next, the sample was centrifuged at
20,160g, 4 C for 30 min in order to separate free
amino acids from precipitated proteins. Before further
procedures, both supernatant and the protein pellet were
dried in a speedvac (miVac centrifugal vacuum
concentrator, Genevac, Ipswich, UK) and in a freeze
dryer, respectively. The dry weight of the protein pellet
was then recorded. As with the CSF, both the dried
supernatant and the protein pellet were hydrolyzed
(500 ll 6 M HCl; 20 h; 110 C) and freeze-dried
overnight. This was followed by reconstitution in 500 ll
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ﬁltration (Ultrafree centrifugal ﬁlters, 0.22 lm, Merck
Millipore, Cork, Ireland or nanosep MF 0.2 lm, Pall Life
Sciences, Dreieich, Germany). The clear solution was
transferred to a microtube and lyophilized. The
derivatization procedure for the free hydrolyzed fraction
was the same as for CSF. The hydrolyzed protein
fraction, on the other hand, went through sequential
dilutions before derivatization. The dried sample was
reconstituted in 15–20-ll 20 mM HCl to a concentration
corresponding to approximately 0.4-mg hydrolyzed
protein/ll for whole blood, and 0.28 mg/ll for plasma. All
samples were diluted in two steps to reach a ﬁnal
concentration of 0.025-mg hydrolyzed protein/ll. From
this solution, 20 ll was used for the derivatization
reaction, equaling 0.5-mg hydrolyzed protein. When only
diluting the samples in borate buﬀer (Waters AccQ-Tag
Ultra kit, Waters, Milford, MA, USA), the pH of the ﬁnal
derivatization solution of a majority of the samples was
below the pH (8.2–9.7) recommended for an optimal
derivatization reaction (Cohen and Michaud, 1993).
Therefore, pH was raised in all samples during dilution.
The two-step dilution procedure was initiated by dilution
in borate buﬀer and 2 M NaOH, yielding approximately
0.04-mg hydrolyzed protein/ll. NaOH was added in a
volume corresponding to approximately 8.3 and
7.2 lmol NaOH/mg hydrolyzed protein in whole blood
and plasma, respectively. In the second dilution step the
samples were diluted in borate buﬀer to a concentration
of 0.025-mg hydrolyzed protein/ll, and the ﬁnal solution
used for the derivatization reaction. The addition of
NaOH during dilution resulted in a pH increase of 0.5–
1 units, compared to dilutions made in borate buﬀer only.
Accordingly, the pH was 8–9 (measured with pH-indicator
strips due to small sample volumes, pH 0–14,
MColorpHast, Merck, Darnstadt, Germany) prior to
derivatization. For derivatization, 20 ll of NaOH/borate-
containing 0.025 mg/ll-solution (corresponding to a total
amount of 0.5-mg hydrolyzed protein) was added to 80-
ll borate buﬀer and 20-ll AQC.
UHPLC and mass spectrometry
BMAA analyses were performed using a Xevo triple
quadrupole mass spectrometer connected to an Acquity
ultra performance liquid chromatography (UPLC)
instrument (Waters, Milford, MA, USA). Separation was
performed on an Acquity UPLCBEH C18 (1.7-lm
particle size, 2.1  100-mm column; Waters, Milford,
MA, USA) at 55 C and a gradient elution (solvent A,
0.01% formic acid, 0.05% ammonia in water, solvent B,
MeOH with 0.01% formic acid), delivered at a ﬂow rate
of 600 ll/min. The gradient was as follows 0.0 min, 0.1%
B; 0.54 min, 0.1% B (curve 6); 4.00 min, 55.0% B (curve
5); 4.10 min, 100% B (curve 7); 5.10 min, 100% B (curve
6); 5.20 min, 0.1% B (curve 6) and 6.20 min, 0.1% B
(curve 6). Ion source parameters were: capillary voltage
4 kV, cone voltage 30 V, source temperature 150 C,
desolvation temperature 550 C, desolvation gas ﬂow
1000 L/h and collision gas ﬂow 0.15 ml/min. To minimize
contamination of the interface the ﬂow was diverted to
waste between 0 min and 1.2 min, data were recordedfrom 1.2 min to 3.5 min, and thereafter the ﬂow was
again diverted to waste. Electrospray ionization (ESI)
was employed and the mass spectrometer was set to
positive ion mode using multiple reaction monitoring
(MRM) of ﬁve diﬀerent transitions. The transitions used
were (459.18 > 119.1) which is common for AEG,
BMAA and DAB; (459.18 > 258.1) which is the speciﬁc
fragment for BMAA; (459.18 > 188.1) speciﬁc for DAB
(Spa´cˇil et al., 2010), (459.18 > 214.1) speciﬁc for AEG
(Banack et al., 2011) and (462.2 > 122.1) speciﬁc for
D3-BMAA (Fig. 1). Collision energy was 26 V for all
transitions. Standard solutions containing BMAA, DAB
and AEG were injected repeatedly during analysis of each
sample set to ensure separation, and to monitor the reten-
tion time of each compound throughout the analysis.
Injection volume was 10 ll for CSF and 20 ll for whole
blood and plasma samples. To ensure that no carry-over
between injections occurred and to improve column life-
length, approximately every seventh sample was followed
by a columnwash, an equilibration step and the injection of
a blank sample. Smoothing was performed on all mass
spectra using the MassLynx v4.1 (Waters, Milford, MA,
USA) built-in mean algorithm, with either 1  2 or 2  2
for CSF samples and whole blood/plasma samples
respectively.Detection criteria for BMAA. The minimum criteria for
acceptance of a peak were signal-to-noise ratio
(S/N)P 4 and a minimum peak width of 2 s. To ensure
correct assignment of BMAA, retention time as well as
both the qualiﬁer (459.18 > 258.1) and quantiﬁer
fragment (459.18 > 119.1) were considered. Instrument
limit of detection (LOD) for BMAA was determined as
the lowest concentration with peaks of [119.1]m/z and
[258.1]m/z with (S/NP 4), at the correct retention time
(±5% compared to a BMAA standard in the same
sample set), and was 3.6 fmol or 0.42 pg on-column.
The criteria for determining LOD in sample matrices
were the same as for instrument LOD, but with the
additional requirement that the ratio (119.1/258.1) was
correct within ±20% (relative standard deviation; RSD)
compared to the mean ratio (5.4), calculated from
BMAA in borate buﬀer (see standard curve Fig. A.1A
(Appendix)). The limit of quantiﬁcation (LOQ) in sample
matrix was set at the concentration where (in addition to
fulﬁlling the criteria for LOD) the area of [119.1]m/z and
[258.1]m/z and their ratio did not vary more than ±20%
(RSD) in between the replicates. When using less than
three replicates for the standard curve (as for the CSF
matrix where n= 2) the criteria for LOQ in matrix, as
stated above, were not applicable. Instead, S/NP 30
were required for both the [119.1]m/z and [258.1]m/z
fragments, as this normally resulted in replicates
keeping within %RSD± 20 of the 119/258 ratio.Calibration curve CSF. A standard curve with ﬁve
BMAA concentration levels (n= 2 for each
concentration) was constructed using a human CSF
sample previously determined as negative for BMAA
(Fig. A.1B (Appendix)). LOD and LOQ in the hydrolyzed
protein fraction was determined to 0.12 pmol (14.3 pg)
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Table 1. BMAA (b-N-methyl-L-alanine) in cerebrospinal ﬂuid (CSF) in
Swedish ALS patients and non-ALS individuals. The ALS patients
and non-ALS individuals were age- and gender-matched. The con-
centrations given represent pg BMAA per ml CSF in hydrolyzed free or
L. Berntzon et al. / Neuroscience 292 (2015) 137–147 141BMAA on-column (equals 57 pg BMAA/ml CSF) and the
standard curve was linear up to 1.7 pmol (197 pg) and
r2 = 0.96 (Table A.1; Fig. A.1B (Appendix)).protein fraction.
Sample Age (year) Gender CSF pg/ml (n= 1)
Free
fraction
Protein
fraction
ALS-patients
ALS1 68 M 78.0 96.6
ALS2 63 F ND ND
ALS3 78 F ND ND
ALS4 58 M ND ND
ALS5 46 M ND ND
ALS6 79 F ND ND
ALS7 69 M ND ND
ALS8 85 M ND ND
ALS9 66 F ND ND
ALS10 71 M ND ND
ALS11 61 M ND ND
ALS12 59 M ND ND
Non-ALS individuals
non-ALS1 31 M ND 234.5*
non-ALS2 42 M ND 540.9*
non-ALS3 76 M ND ND
non-ALS4 65 F ND ND
non-ALS5 32 M ND NDCalibration curve whole blood. A standard curve with
six BMAA concentrations (n= 5) was made from the
whole-blood protein fraction of a sample previously
determined as negative for BMAA (Fig. A.1C (Appendix)).
Also, a standard curve in the free hydrolyzed fraction of
the same sample was prepared with six concentrations of
BMAA (n= 4). The LOD was 0.75 pmol (89 pg) BMAA
on-column (equals 171 ng BMAA/ml whole blood) for the
protein fraction and 7.5 pmol (892 pg) BMAA on-column
(equals 53 ng BMAA/ml whole blood) for the free
hydrolyzed fraction. LOQ was determined to 7.5 pmol
(892 pg) BMAA on-column (equals 1.7 lg BMAA/ml
whole blood) for the protein fraction and 18.9 pmol
(2.2 ng) BMAA on-column (equals 134 ng BMAA/ml
whole blood) for the free hydrolyzed fraction (Table A.1
(Appendix)). The linear range was between 0.75 and
43 pmol on-column (r2 = 0.99) for the protein fraction.
For the free hydrolyzed fraction only two concentrations
of the standard curve reached the criteria for BMAA
detection, hence no curve was established. The
calibration curves in whole blood were also applied for
plasma samples.non-ALS6 22 M ND ND
non-ALS7 68 F ND ND
non-ALS8 35 F ND ND
non-ALS9 69 M ND ND
non-ALS10 81 M ND ND
non-ALS11 60 M ND ND
non-ALS12 71 M ND ND
non-ALS13 71 M ND ND
ND: not detected (concentration < LOD/LOQ); LOD: limit of detection; LOQ: limit
of quantiﬁcation.
* Quantiﬁcation was made without correction for internal standard (D3-BMAA),Quantiﬁcation method in CSF. For quantiﬁcation of
BMAA in human samples, 43-pmol D3-BMAA was
added as internal standard to each sample prior to the
acid hydrolysis and recovery was determined and used
to compensate for sample loss during work-up. As D3-
BMAA is highly soluble and will follow the free fraction
during the sample work-up it was added to the samples
prior to acid hydrolysis, and can only account for losses
during and after hydrolysis.see Result section.RESULTS
UHPLC–MS/MS was used to analyze the presence of the
neurotoxin BMAA in human samples from Sweden
(Fig. 1). Out of the 25 individuals tested, BMAA was
detected in three (12%), while not in the remaining 22
individuals (88%) (Table 1). Notably, only one BMAA-
positive sample derived from an ALS-patient (ALS1),
while the other two were from non-ALS individuals (non-
ALS1 and non-ALS2; controls).Fig. 1. UHPLC–MS/MS chromatograms illustrating the presence of BMAA
showing the multiple reaction monitoring (MRM) transitions and total ion cou
relative abundance and the x-axis is retention time in minutes. (A) Elution p
glycine), BMAA (b-N-methyl-L-alanine) and DAB (L-2-4-diaminobutyric acid)
Swedish ALS patient (ALS1) showing the MRM transitions 459.1 > 258.1
2.83 min), as well as the transition for deuterated BMAA (D3-BMAA) at 462.2
transition 459.1 > 119.1 for AEG is apparent at retention time 2.77 min and D
of a Swedish ALS patient (ALS1) showing the MRM transitions 459.1 > 25
2.85 min), as well as the transition for deuterated BMAA (D3-BMAA) at 462.2
transition 459.1 > 119.1 for AEG is apparent at retention time 2.78 min (botto
not diagnosed with ALS (non-ALS1) showing the MRM transitions 459.1 >
2.81 min) as well as the TIC (bottom panel). (E) BMAA in the CSF protein
showing the MRM transitions 459.1 > 258.1 (top panel, Rt 2.83 min) and 45
panel). The MRM transition 459.1 > 119.1 for DAB is apparent at retention tim
3The three BMAA-positive samples were retrieved from
the human CSF, with the highest concentration found in
one control/non-ALS individual (non-ALS2) (Table 1).
BMAA was detected in the hydrolyzed protein fraction of
all three individuals, but also in the free hydrolyzed
fraction of the ALS-patient (ALS1) (Table 1; Fig. 1). By
using D3-BMAA as an internal standard, BMAA was
conﬁdently quantiﬁed in the CSF of the ALS patient
(ALS1; Table 1). The hydrolyzed free and protein(b-N-methyl-L-alanine) in human cerebrospinal ﬂuid. Chromatograms
nt (TIC) for the BMAA-positive samples found. The y-axis represents
atterns for standard solutions of the isomers AEG (N-(2-aminoethyl)
. (B) BMAA in the free fraction of cerebrospinal ﬂuid (CSF) from a
(middle panel, Rt 2.84 min) and 459.1 > 119.1 (bottom panel Rt
> 122.1 (top panel, Rt 2.83 min) used as internal standard. The MRM
AB at 2.93 min (bottom panel). (C) BMAA in the CSF protein fraction
8.1 (middle panel, Rt 2.86 min) and 459.1 > 119.1 (bottom panel Rt
> 122.1 (top panel, Rt 2.84 min) used as internal standard. The MRM
m panel). (D) BMAA in the CSF protein fraction of a Swedish individual
258.1 (top panel, Rt 2.81 min) and 459.1 > 119.1 (middle panel, Rt
fraction of a Swedish individual not diagnosed with ALS (non-ALS2)
9.1 > 119.1 (middle panel, Rt 2.84 min), as well as the TIC (bottom
e 2.92 min (middle panel) and in the TIC (bottom panel, Rt 2.93 min).
Table 2. Summary of BMAA (b-N-methyl-L-alanine) analyses performed in human material. Given are the number and types of samples analyzed, analytical method, LOD/LOQ in sample matrix and BMAA
results. Data set No.1–5 refers to examinations of post mortem stored brains; data set No. 6–7 refers to ante mortem cerebrospinal ﬂuid (CSF) and blood.
Data set
No.
Human samples and their
geographical origin
Tissue/ﬂuid Fraction
analyzed
Method of analysis LOD/LOQ (in sample
matrix)
Number of BMAA positive
samples/total samples
BMAA
concentrations
Reference
1 Guam
a. 6 ALS-PDC
b. 2 ctrl
Canada
c. 2 AD
d. 13 ctrl
Superior frontal
gyrus
(a) Free
(b) Free and
protein
(a, b) HPLC-FLD*
MS veriﬁcation1
AQC-derivatization
(a) Not given
(b) Not clearly
stated2
(a) a. Not given3
b. No results given
c. Not given3
d. 0/13
(b) a. 6/6
b. 1/2
c. 2/2
d. 0/13
(a) a.6 lg/g
(average)
b. Not given
c. 6.6 lg/g
(average)
d. –
(b) a. 3.3–1190 lg/
g
b. 48–82 lg/g
c. 3.4 and
264 lg/g
d. –
Cox et al. (2003) (a)
Murch et al. (2004a) 4 (b)
2 Canada
a. 7 AD
b. 1 ctrl
Frontal cortex,
temporal cortex,
parahippocampal
gyrus, caudate,
cerebellum
Protein HPLC-FLD*
MS veriﬁcation1
AQC-derivatization
Not given a. 6/7
b. 0/1
a. 25.9–235.6 lg/g
b. –
Murch et al. (2004b)5
3 Guam
a. 8 PDC
b. 2 ctrl
USA
c. 5 AD
d. 5 ctrl
(c) Frontal cortex,
temporal cortex,
cerebellum, middle
frontal gyrus
(d, e) Frontal cortex,
temporal cortex
(f) Frontal cortex,
temporal cortex,
(c) Free
(d, e) Free
and protein
(f) Free
(c) HPLC-FLD*
FMOC-derivatization
(d, e) GC–MS*, IS,
ECF-derivatization*
(f) GC  GC-
TOFMS*, TMS-
derivatization
(c) 1 pmol/ not given
(d, e) Free fraction:
0.1/0.2 lg/g, protein
fraction: 5/10 lg/g
(f) 0.7 ppb/1 ppb
(4.5 ng/g)
(c,d,e,f) 0/20 (c,d,e,f) – Montine et al. (2005) (c)
Snyder et al. (2009a)6 (d)
Snyder et al. (2009b) (e)
Snyder et al. (2010) (f)
4 USA
a. 13 ALS
b. 8 HD
c 12 AD
d. 12 ctrl
Frontal cortex,
temporal cortex,
caudate, spinal cord
Protein HPLC-FLD*
MS/MS veriﬁcation1
AQC-derivatization
2/10 ng on-column a. 13/13
b. 1/8
c. 12/12
d. 2/12
a. 31–256 lg/g
b. 11 lg/g
c. 10–228 lg/g
d. 39 and 45 lg/g
Pablo et al. (2009)
5 France
2 ALS
Frontal lobe,
hippocampus
Free LC–MS/MS*
underivatized
Not clearly
stated/20 ng/g
0/2 – Combes et al. (2014)
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BMAA/ml CSF, respectively. The BMAA concentrations
in the hydrolyzed protein fractions of the non-ALS1 and
non-ALS2 samples were above the LOQ. However,
these were analyzed prior to the availability of D3-BMAA
to our research group and could therefore not be
quantiﬁed as accurately as sample ALS1. However, by
assuming 100% recovery to avoid overestimations, the
minimum BMAA concentrations were calculated to be
234.5 and 540.9 pg BMAA/ml CFS in the protein fraction
of sample non-ALS1 and non-ALS2, respectively.
Hence, the BMAA concentrations in the CSF protein
fractions of these control individuals were approximately
2–6 times higher than that found in the CSF protein
fraction of the ALS1 patient (Fig. 1; Table 1). The fact
that BMAA was not present in 88% of the human CSF
samples suggests that these were devoid of BMAA, or
that the BMAA concentrations were below the LOD/LOQ
of the analytical method used here.
BMAA was not detected in whole blood or plasma in
any of the 25 individuals tested, irrespective of whether
the hydrolyzed protein or free fractions were analyzed
(Table A.2 (Appendix)). It cannot be excluded that
BMAA-positive samples escaped detection due to the
relatively high LOD (on-column) for whole blood
compared to CSF, being 6 and 63 times higher for the
hydrolyzed protein and free fraction, respectively.DISCUSSION
Today there is general agreement that capacity to
biosynthesize the neurotoxic BMAA is a trait held by
globally widespread phytoplankton, although reported
concentrations vary considerably (Faassen et al., 2012;
Faassen, 2014). As for other cyanobacterial toxins, little
is known about the role of BMAA in these organisms
(Downing et al., 2011, 2015; Scott et al., 2014).
Diverging interpretations of the eﬀects of BMAA in other
organisms also exist (Spencer et al., 1987; Perry et al.,
1989; Matsuoka et al., 1993; Cruz-Aguado et al., 2006;
Chiu et al., 2012; Lee and McGeer, 2012).
Our results show for the ﬁrst time that BMAA,
previously reported to be present in food webs of a
brackish water body in a temperate climate (the Baltic
Sea; see Jonasson et al., 2010), can be recovered from
humans potentially exposed to Baltic Sea BMAA-‘contami-
nated’ food items (ﬁsh, shellﬁsh). Although BMAA was
detected in only a few of the 25 individuals tested (12%),
the data presented here support the hypothesis that
BMAA in the Baltic Sea environment may bioaccumulate
in aquatic organisms and reach humans, thereby poten-
tially constituting a threat to human health (Jonasson
et al., 2010). The risk of human BMAA exposure in the
Baltic Sea area is further corroborated by a recent study
reporting the presence of BMAA in shellﬁsh and ﬁshes
(locally caught and imported) sold in Swedish food mar-
kets (Jiang et al., 2014b). Our ﬁndings are also noteworthy
in view of the documented enhanced Baltic Sea cyanobac-
terial blooms in recent decades (Kahru and Elmgren,
2014), known to produce BMAA (Jonasson et al., 2010);
and perhaps particularly in view of the reported increase
144 L. Berntzon et al. / Neuroscience 292 (2015) 137–147in ALS incidence rates in Sweden from 1991 to 2005, the
reason for which is unknown (Fang et al., 2009).
The present observations are, to the best of our
knowledge, the ﬁrst to demonstrate the occurrence of
BMAA in human individuals ante mortem (see Table 1),
and to quantify BMAA in human material using UHPLC–
MS/MS. The BMAA was found in the CNS, more
speciﬁcally in the CSF, while no BMAA was observed in
the blood (whole blood and plasma) of the tested
individuals.
BMAA was present in the CSF protein fraction or in
peptides of the free CSF fraction and was released
only after acid hydrolysis. The synthesis of these
proteins/peptides and their association to BMAA most
likely occurred in the CNS (Xie et al., 2013), although
some may have been transported into the CNS
(Ghasemzadeh et al., 2008). The CSF is an extension
of the extracellular space of the CNS and is known to
reﬂect its contents with regard to many low molecular
weight substances (Saunders et al., 1999). Free BMAA
have the ability to pass the blood–brain barrier, even
though the transport is relatively ineﬀective despite pos-
sibly making use of the large neutral amino acid carrier
(Duncan et al., 1991; Smith et al., 1992) or cerebral
capillary transfer (Xie et al., 2013). Association/in-
corporation of BMAA into proteins has been suggested
in animal studies (Karlsson et al., 2009a, 2014), and
the ability to misincorporate BMAA during protein biosyn-
thesis was recently demonstrated in human cells
(Dunlop et al., 2013) as well as in a cell-free protein
expression system (Glover et al., 2014). These ﬁndings
support the proposed BMAA-protein bioaccumulation
mechanism (Murch et al., 2004b).
The absence of BMAA in the free amino acid fraction
(non-hydrolyzed) of the CSF may indeed indicate that
most BMAA ends up as associated with, or incorporated
into, proteins in human organs. Alternatively, the BMAA
concentrations in free form were below our LOD.
Furthermore, free BMAA in the human CNS could
potentially escape detection due to a short half-life,
known to be less than one day in the CNS of rats
(Duncan et al., 1991; Smith et al., 1992). The reported
rapid binding of BMAA to speciﬁc regions of the brain in
neonatal mice also implies that free BMAA perhaps reside
in the CSF for only a short time span (Karlsson et al.,
2009b). In addition, free BMAA in the plasma and brain
of BMAA-injected mice steadily decreased (within days),
while the protein-associated BMAA levels in the brain
reached a plateau (within hours) and accounted for most
of the BMAA detected one week later (Xie et al., 2013).
Due to the variety of proteins in the human CNS with dif-
ferent localizations, functions, and half-lives, the persis-
tence of protein-associated BMAA in the CNS might
vary considerably. However, both free and protein-associ-
ated BMAA (single subcutaneous injection) were cleared
from the rat brain within months (Karlsson et al., 2014). In
addition, the dietary exposure to BMAA most likely ﬂuctu-
ates over time.
The lack of BMAA in whole blood/plasma in the 25
individuals tested here (free and protein fraction) could
be a consequence of a more rapid clearance of BMAAfrom the blood than from the CNS, as previously
reported (Xie et al., 2013). Or alternatively, it may be
due to the higher detection limit of BMAA in the blood than
in CSF for our methodological approach (Table A.1
(Appendix)).
As seen in Table 2, some earlier studies detected
BMAA in the brain of the majority of tested patients that
had deceased from ALS-PDC, AD and ALS (Cox et al.,
2003; Murch et al., 2004a,b; Pablo et al., 2009); while in
other studies no BMAA was found in the brains of patients
deceased from the same disorders (Montine et al., 2005;
Snyder et al., 2009a,b, 2010; Combes et al., 2014).
Likewise, BMAA was not detected in the CSF (or blood)
in a similar study comprising 12 Swedish ALS patients
and 10 controls, using an approach with a slightly higher
detection limit than in the present study (Kushnir and
Bergquist, 2009; Table 2; Table A.1 (Appendix)). Hence,
our data, with BMAA found in 12% of the tested individu-
als ante mortem fall between the previous reports. It
clearly conﬁrms the presence of BMAA in the human
CNS, although the data do not support the idea of
BMAA being resident speciﬁcally in ALS patients. The
low number of BMAA positives prevents valid generaliza-
tions regarding the distribution of BMAA between ALS
patients and controls. Due to the ‘liquid’ nature of CSF,
the BMAA concentrations detected in our study (pg/ml)
are not directly comparable to the BMAA concentrations
reported for post mortem brain material (lg/g).
Discrepancies between the diﬀerent studies (Table 2)
may be explained by actual diﬀerences in the patient
cohorts examined: geographic and cultural diﬀerences,
life strategies, variations in the overall genetic susceptibil-
ity or by the organs examined (including post and ante
mortem), but perhaps more likely by diﬀerences in the
analytical approaches used (ours being one of only three
studies using MS/MS for quantiﬁcation).
Even though our study does not support previous
ﬁndings of BMAA prevailing in the CNS of patients
suﬀering from speciﬁc neurodegenerative diseases, the
data do not rule out BMAA as a potential environmental
risk factor in the pathogenetic process underlying
neurodegenerative disorders. Rather, the fact that
BMAA, by now a proven neurotoxin, can be retrieved
from the CNS of human individuals is alarming. As
indicated by the rare occurrence of ALS (approximately
2.5 cases/100,000 inhabitants yearly in Sweden) (Fang
et al., 2009), BMAA may not act as a stand-alone etiologi-
cal risk factor but perhaps as a potentiating agent in con-
cert with other environmental factors. Hence, the ﬁnding
of BMAA in the human CSF, including in one ALS patient,
stresses the need for continued investigations in regard to
the role of BMAA in the terminal neurodegenerative dis-
ease ALS, as this could open a potential avenue for eﬀec-
tive treatments and cures.Acknowledgments—Financial support from the Baltic Ecosystem
Adaptive Management program (BEAM, Stockholm University),
the Baltic Sea 2020 and Olle Engqvist, Byggma¨stare
Foundations, is gratefully acknowledged. We thank Yvonne
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APPENDIXCSF: cerebrospinal ﬂuid.
Table A.2. BMAA (b-N-methyl-L-alanine) in cerebrospinal ﬂuid (CSF),
whole blood and plasma from Swedish ALS patients and non-ALS
individuals. Values represent pg BMAA per ml CSF in hydrolyzed free
or protein fractions.
Sample CSF pg/ml
(n = 1)
Whole blood
(n= 3)
Plasma
(n= 3)
Free
fraction
Protein
fraction
Free
fraction
Protein
fraction
Free
fraction
Protein
fraction
ALS-patients
ALS1 78.0 96.6 ND ND ND ND
ALS2 ND ND ND ND ND ND
ALS3 ND ND – – – –
ALS4 ND ND ND ND ND ND
ALS5 ND ND ND ND ND ND
ALS6 ND ND – – – –
ALS7 ND ND ND ND ND ND
ALS8 ND ND ND ND ND ND
ALS9 ND ND ND ND ND ND
ALS10 ND ND ND ND ND ND
ALS11 ND ND ND ND ND ND
ALS12 ND ND ND ND ND ND
Non-ALS individuals
non-ALS1 ND 234.5* ND ND ND ND
non-ALS2 ND 540.9* ND ND ND ND
non-ALS3 ND ND – – – –
non-ALS4 ND ND – – – –
non-ALS5 ND ND ND ND ND ND
non-ALS6 ND ND – – – –
non-ALS7 ND ND – – – –
non-ALS8 ND ND – – – –
non-ALS9 ND ND ND ND ND ND
non-ALS10 ND ND ND ND ND ND
non-ALS11 ND ND ND ND ND ND
non-ALS12 ND ND – – – –
non-ALS13 ND ND ND ND ND ND
ND: not detected (concentration < LOD/LOQ); dash: not analyzed.
LOD: limit of detection; LOQ: limit of quantiﬁcation.
* Quantiﬁcation was made without correction for internal standard (D3-BMAA),
see Result section.
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L. Berntzon et al. / Neuroscience 292 (2015) 137–147 147Amount BMAA on column (pg)Fig. A.1. BMAA (b-N-methyl-L-alanine) calibration curves in buﬀer
and protein fraction of cerebrospinal ﬂuid (CSF) and whole blood. (A)
Calibration curve in borate buﬀer (0.64–5094 pg BMAA on column,
n= 5). (B) Calibration curve (14.3–197 pg BMAA on column, n= 2)
obtained by spiking BMAA into hydrolyzed protein extracts of human
cerebrospinal ﬂuid (CSF). (C) Calibration curve (89–5094 pg BMAA
on column, n= 5) obtained by spiking BMAA into hydrolyzed protein
extracts of human whole blood. Points in graph A and C represent
mean values with error bars denoting standard deviation. In graph B,
each point represents the peak area (m/z 119) of the speciﬁc
replicate.(Accepted 16 February 2015)
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